Hosted on MSN2d
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?
Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON ...
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...
Positive Report for Beam Therapeutics (BEAM) from Bernstein
Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...
What is Leerink Partnrs’ Forecast for BEAM FY2024 Earnings?
Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts
Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.
Beam Therapeutics to encore data from BEACON Phase 1/2 trial of Beam-101
Beam Therapeutics (BEAM) announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in ...
news.stocktradersdaily3d
(BEAM) Investment Report
Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM. Type ...
Nasdaq4d
Beam Therapeutics to Present Data from BEACON Phase 1/2 Trial of BEAM-101 for Sickle Cell Disease at 2025 Tandem Meetings
Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the ...
Morningstar4d
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...